These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 9537248)

  • 41. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy.
    de Cremoux P; Ravery V; Podgorniak MP; Chevillard S; Toublanc M; Thiounn N; Tatoud R; Delmas V; Calvo T; Boccon-Gibod L
    Eur Urol; 1997; 32(1):69-74. PubMed ID: 9266235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy.
    Olsson CA; de Vries GM; Raffo AJ; Benson MC; O'Toole K; Cao Y; Buttyan RE; Katz AE
    J Urol; 1996 May; 155(5):1557-62. PubMed ID: 8627821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
    Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
    Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detecting circulating prostate cells in patients with clinically localized prostate cancer: clinical implications for molecular staging.
    Llanes L; Páez A; Ferruelo A; Luján M; Romero I; Berenguer A
    BJU Int; 2000 Dec; 86(9):1023-7. PubMed ID: 11119095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
    Okubo Y; Ito T
    Hinyokika Kiyo; 1999 Jan; 45(1):25-30. PubMed ID: 10086262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Schnall M; Tomaszewski JE; Wein A
    J Clin Oncol; 1996 Jun; 14(6):1770-7. PubMed ID: 8656245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy.
    Yates DR; Rouprêt M; Drouin SJ; Comperat E; Ricci S; Lacave R; Sèbe P; Cancel-Tassin G; Bitker MO; Cussenot O
    Prostate; 2012 Sep; 72(12):1382-8. PubMed ID: 22228175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction.
    Su SL; Boynton AL; Holmes EH; Elgamal AA; Murphy GP
    Semin Surg Oncol; 2000; 18(1):17-28. PubMed ID: 10617893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reverse transcriptase-polymerase chain reaction assays for prostate cancer.
    Olsson CA; de Vries GM; Buttyan R; Katz AE
    Urol Clin North Am; 1997 May; 24(2):367-78. PubMed ID: 9126234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer.
    Ellis WJ; Vessella RL; Corey E; Arfman EW; Oswin MM; Melchior S; Lange PH
    J Urol; 1998 Apr; 159(4):1134-8. PubMed ID: 9507816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics.
    Ennis RD; Katz AE; de Vries GM; Heitjan DF; O'Toole KM; Rubin M; Buttyan R; Benson MC; Schiff PB
    Cancer; 1997 Jun; 79(12):2402-8. PubMed ID: 9191530
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
    Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
    Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread.
    Renneberg H; Friedetzky A; Konrad L; Kurek R; Weingärtner K; Wennemuth G; Tunn UW; Aumüller G
    Urol Res; 1999; 27(1):23-7. PubMed ID: 10092150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of RT-"nested" PCR of prostate specific antigen to detect hematogenous neoplastic cells in patients with prostate adenocarcinoma.
    Sardi I; Piazzini M; Ponchietti R; Fatini C; Di Loro F; Guazzelli R
    J Mol Med (Berl); 1997 Oct; 75(10):751-7. PubMed ID: 9382999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of circulating tumor cells in men with localized prostate cancer.
    Seiden MV; Kantoff PW; Krithivas K; Propert K; Bryant M; Haltom E; Gaynes L; Kaplan I; Bubley G; DeWolf W
    J Clin Oncol; 1994 Dec; 12(12):2634-9. PubMed ID: 7527455
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific membrane antigen-derived primers in a nested reverse transcription polymerase chain reaction for detecting prostatic cancer cells.
    Saimoto A; Saito S; Murai M
    Jpn J Cancer Res; 1999 Feb; 90(2):233-9. PubMed ID: 10189895
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer.
    Ignatoff JM; Oefelein MG; Watkin W; Chmiel JS; Kaul KL
    J Urol; 1997 Nov; 158(5):1870-4; discussion 1874-5. PubMed ID: 9334620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
    Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
    Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.